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Abstract
Point mutations in TBX1 can recapitulate many of the structural defects of 22q11 deletion syndromes (22q11DS), usually
associated with a chromosomal deletion at 22q1.2. 22q11DS often includes specific cardiac and pharyngeal organ
anomalies, but the presence of characteristic craniofacial defects is highly variable. Even among family members with a
single TBX1 point mutation but no cytological deletion, cleft palate and low-set ears may or may not be present. In theory,
such differences could depend on an unidentified, second-site lesion that modifies the craniofacial consequences of TBX1
deficiency. We present evidence for such a locus in a mouse model. Null mutations of chordin have been reported to cause
severe defects recapitulating 22q11DS, which we show are highly dependent on genetic background. In an inbred strain in
which chordin
2/2 is fully penetrant, we found a closely linked, strong modifier—a mutation in a Tbx1 intron causing severe
splicing defects. Without it, lack of chordin results in a low penetrance of mandibular hypoplasia but no cardiac or thoracic
organ malformations. This hypomorphic Tbx1 allele per se results in defects resembling 22q11DS but with a low penetrance
of hallmark craniofacial malformations, unless chordin is mutant. Thus, chordin is a modifier for the craniofacial anomalies of
Tbx1 mutations, demonstrating the existence of a second-site modifier for a specific subset of the phenotypes associated
with 22q11DS.
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Introduction
In approximately 1 in 4000 human births, syndromic congenital
malformations are associated with deletions in chromosomal
region 22q11.2. DiGeorge syndrome (OMIM 188400), velocar-
diofacial syndrome (OMIM 192430), and related syndromes are
all associated with this deletion; these are collectively called the
22q11 deletion syndromes, 22q11DS [1]. At least 20 genes are
contained within the region typically deleted, the DiGeorge
Critical Region (DCR).
To understand the roles of particular DCR genes in the etiology
of 22q11DS, the functions of many of these genes have been
assessed in the mouse. Tbx1 null homozygotes show severe defects
in all the structures variably affected in these syndromes [2,3,4],
while heterozygotes show aortic arch artery defects similar to some
mildly affected patients [2]. Several different point mutations in
TBX1 have been identified in patients with 22q11DS but without
cytological deletions at 22q11 [5,6]. Thus, defective TBX1
function is a key factor in the pathogenesis of the 22q11DS
malformations.
Despite the identification of the DCR, and the key role of TBX1
in particular, the genetics of 22q11DS pathogenesis remains
unclear. Significant numbers of 22q11DS patients don’t possess
deletions at 22q11.2 or knownTBX1 point mutations, while
deletions in other regions of the genome have been observed
[7,8]. These and related considerations suggest that other loci, as
yet unknown, play an important role in the etiology of 22q11DS
[9]. In mouse models, mutations in Crkl, which lies in 22q11.2, and
in Fgf8, which is unlinked, have both been shown to modulate the
developmental phenotype by enhancing the effects of a Tbx1 null
mutation [10,11]. However, none of the genetic results to date
suggest an explanation for the high variability of disease symptoms
among 22q11DS patients, or why subsets of patients present with
particular structural malformations but not others.
Mice lacking chordin (Chrd), a dedicated antagonist of Bone
Morphogenetic Proteins (BMPs), have been reported to show a
phenotype recapitulating many structural features of 22q11DS,
and very similar to that of Tbx1 null embryos [12,13]. Especially
given that both genes are expressed in or around the pharyngeal
endoderm during early organogenesis, this implied a mechanistic
link between BMP antagonism and Tbx1 function. Consistent with
this, reduced levels of Tbx1 message were observed in the
pharyngeal region of Chrd
2/2 embryos; moreover, Chrd transcript
injected into early Xenopus embryos could increase the endog-
enous Tbx1 transcriptional level [12]. Taken together, these results
suggested that chordin acts in the pharyngeal region to protect
Tbx1 expression from inhibition by local BMPs. However, as
detailed below, our breeding of Chrd in different wildtype genetic
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Chrd entirely, yet exhibit no resemblance to 22q11DS or Tbx1
mutants. Such results reveal that an additional, unknown genetic
mechanism was at play in the generation of these phenotypes.
Here we report our elucidation of the relationship between Chrd,
Tbx1, and the 22q11DS phenotypes.
Results
The previously reported Chrd
2/2 null phenotype is a completely
penetrant constellation of defects – which we call hereafter the ‘full
phenotype’ – that includes dysmorphic ear (Figure 1A, B), absence
of thymus (athymia), persistent truncus arteriosus (PTA), abnormal
aortic arch artery structure (Figure 1C–E), cleft palate (Figure 1F–
G). This spectrum of defects is virtually identical to those of Tbx1
null homozygotes (see Figure S1, available online).
However, Chrd phenotypes are highly dependent on genetic
background. We observed that Chrd
2/2 embryos in an inbred
129S6/SvEv (129S6) genetic background displayed 100% pene-
trance of this full phenotype. In contrast, mutant embryos in
C57B6/J (B6) and random outbred genetic backgrounds were
viable and lacked all but a low penetrance of mild craniofacial
phenotypes, primarily involving the mandible. This suggested the
existence of a strain-specific modifier. To assess this, we interbred
129S6- and B6.129-Chrd
+/2 animals, generating F1 and F2 hybrid
Chrd
2/2 embryos. We detected no phenotype in F1 Chrd
2/2
embryos, while F2 Chrd
2/2 embryos showed a 44.3% penetrance of
phenotypes (43/97; Figure 1H), suggesting either a 129S6-derived
recessive modifier or B6-derived dominant suppressor. Because
random outbred Chrd homozygotes lacked DGS-like phenotypes,
the former seemed more likely. The F2 hybrid Chrd
2/2 embryos
showed a range of phenotypes, suggesting that the effect of a single
modifier is incompletely penetrant, or that more than one modifier
is present (Figure 1I and Figure S2).
To begin locating the putative modifier(s), we conducted a
genome-wide scan for segregation of a particular 129S6-derived
chromosomal region with the Chrd locus to result in the full
phenotype. Although there was evidence of more than one
potential modifier, the data suggested that such a region resides on
the same chromosome as Chrd (data not shown). In contrast to the
situation in humans, Chrd is near the DCR in mice (Figure 2A),
reflecting a relative chromosomal translocation between Chrd and
the DCR in these species. Since lesions within the DCR are
implicated in similar phenotypes in mouse models [10,14], we
investigated whether a linked modifier might account for the
strain-dependence of the Chrd phenotypes.
Using several SSLP and SNP markers on our F2 recombinant
genomic DNAs, we located a region of 129S6-derived chromosome
segregating with the full Chrd phenotype; this region lay close to the
marker rs4165069, just proximal to the DCR (Figure 2A). These
data imply a physically-linked, recessive lesion specific to the 129S6-
derived DCR area that is associated with the full Chrd
2/2
phenotype.
Because the null phenotype of Chrd in the 129S6 background is
essentially identical to that of Tbx1
2/2, the simplest explanation is
that this region contains a recessive, loss-of-function mutation
affecting Tbx1 activity. If so, the Chrd mutant chromosome and
linked modifier(s) should be unable to complement a Tbx1 null
mutation. Accordingly, we crossed 129S6-Chrd
+/2 with B6-
Tbx1
tm1Bld/+ to generate double heterozygotes, with one Chrd allele
and oneTbx1 allele being nulls created by gene targeting, in trans
on the two cognate chromosomes. Among Chrd
+/2,Tbx1
tm1Bld/+
embryos, 5/12 showed the ‘full phenotype’ and 6/12 showed a
partial DGS-like phenotype. This indicates the Tbx1 null allele
interacts strongly with the Chrd mutant chromosome (Figure 2B). In
contrast, when B6.129-Chrd
+/2 was crossed with B6-Tbx1
tm1Bld/+
mice, no significant phenotype was observed in double heterozy-
gotes (0/15, two cases of asymmetric thymus were detected). Thus
the apparent interaction of theTbx1 null locus with Chrd depends on
a linked sensitizer in the 129S6 background. The simplest
explanation is a cryptic mutation in Tbx1 itself.
Sequencing of Tbx1 revealed a point mutation (G to T) specific
to the 129S6-Chrd
+/2 strain (Figure 2C). We did not find any Tbx1
mutation in B6.129-Chrd
+/2 animals or in random outbred Chrd
mice. Furthermore, we did not detect the mutation in 129S6 wild-
type, other 129-substrains, or in the R1 ES cell line used for Chrd
targeting (Figure S3, [12]). These data suggest that this novel
mutation (Tbx1
G.T) occurred spontaneously during initial Chrd
+/2
ES cell culture or in the establishment of the 129S6-Chrd colony.
Utilizing the Tbx1
G.T mutation as a SNP marker, we addressed
how strongly it segregates with the full phenotype. The high LOD
score suggests that the Tbx1 mutation is indeed a strong modifier
(Figure 2D). Since the mutation is in the boundary region of the
second intron and is predicted to disrupt the splicing factor
recognition sequence (ESEfinder 2.0; Figure 2E) [15,16], we
examined splicing ofTbx1 in 129S6-Chrd
2/2 embryos. We
detected exon skipping and intron retention of Tbx1 mRNA from
such embryos, leaving little of the correct form (Figure 2F). This
suggests that the Tbx1
G.T mutation is at least partly responsible for
the 22q11DS constellation of phenotypes observed in Chrd mutants
in certain genetic backgrounds.
Having determined that a Tbx1 lesion is a linked modifier of
Chrd, we wondered how we observed 44% penetrance of the
22q11DS phenotypes in F2 Chrd
2/2 animals (Figure 1H), instead
of the expected value of 25%. Breeding records and retrospective
Tbx1 genotyping indicated that this resulted from using a subset of
F1 hybrid males as studs that by chance had most often inherited
their mutant Chrd allele from the 129S6 background, and thus
were also carriers of the tightly linked Tbx1
G.T allele (the expected
phenotypic penetrance would be 50% if this were the case for all
Author Summary
A range of structural malformations is associated with
22q11 deletion syndrome (22q11DS), which is usually
associated with microdeletions at chromosome 22q11.2.
Variable defects in cardiovascular, pharyngeal, and cranio-
facial structures occur, but the basis for such variability is
unknown. Mutations in TBX1, a gene within the region
typically deleted, can recapitulate the structural anomalies
of 22q11.2 deletions. However, even among family
members with a single TBX1 point mutation, craniofacial
defects are variable. In theory, such differences could
depend on an unknown, second-site lesion that modifies
the craniofacial consequences of TBX1 deficiency. We
identify such a locus in mouse. In certain strains, lack of the
chordin gene results in a phenotype resembling severe
22q11DS, also seen in mice lacking Tbx1. We find that the
chordin phenotype depends on a closely linked, strong
modifier—a cryptic, partial-function mutation in Tbx1.
Without it, lack of chordin sometimes results in mandibular
truncations but no cardiac or thoracic organ malforma-
tions. This novel Tbx1 allele per se results in defects
resembling 22q11DS, but with a low frequency of hallmark
craniofacial malformations, unless chordin is mutant. Thus
chordin is a modifier for the craniofacial anomalies of Tbx1
mutations, demonstrating the existence of a second-site
modifier for a specific subset of phenotypes associated
with 22q11DS.
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Tbx1
G.T allele to F2 hybrid animals. Our F1 and F2 genotyping
also revealed that Chrd
2/2,Tbx1
+/G.T mice (in which one Chrd null
allele was inherited from the129S6 strain and one from B6) had
very few 22q11DS phenotypes (1/53 for F2 animals; Figure 2D).
To determine the phenotypes resulting from the Chrd null or the
Tbx1
G.T allele individually, we bred 129S6-Chrd
+/2,Tbx1
+/G.T
with 129S6 wild-type mice to generate recombinant animals
(Figure 3A). We genotyped 540 offspring and identified one
recombinant carrying only the Chrd null allele (Chrd
+/2,Tbx1
+/+),
and three carrying only the Tbx1
G.T allele (Chrd
+/+,Tbx1
+/G.T).
We assessed the phenotypic consequences of the isolated
mutations. Animals heterozygous for the Tbx1
+/G.T mutation are
healthy and fully viable, displaying no visible phenotype. We crossed
Tbx1
+/G.T animals to themselves and also to Tbx1
+/null. Analysis of
the three classes of Tbx1 mutant embryos for the DGS phenotype
demonstrates genetic rescue: Tbx1
G.T homozygotes show rescue of
the major craniofacial defects of the Tbx1 null phenotype (n=18),
while the compound heterozygote (Tbx1
G.T/null)i si n t e r m e d i a t e
(n=13), relative to the fully penentrant, strong DGS-like
phenotype of the null homozygote. Thus Tbx1
G.T is a
hypomorphic allele (Figure 3B). That craniofacial development
is much less affected in the hypomorphic homozygote relative to
the null demonstrates that craniofacial structures are more
sensitive to Tbx1 dose than cardiovascular structures, consistent
with a previous report [17].
We also prepared homozygotes for the Chrd allele alone,
recombined away from Tbx1
G.T. These Chrd null homozygotes
did not exhibit phenotypes similar to 22q11DS, but showed a low
penetrance of variable mandibular truncations, comparable in
extent and frequency to what we have observed for B6.129-Chrd
2/2
embryos (Figure 3C–H and Table S1). A previous study revealed
redundant but essential roles of chordin and noggin, another BMP
antagonist, in mandibular outgrowth, during which these BMP
antagonists promote cell survival in the developing 1
st pharyngeal
arch [18]. That study used the outbred Chrd strain, which does not
carry the Tbx1 hypomorphic allele. Our study confirms a role for
chordin in promoting mandibular development. Interestingly, we
also observed a severe mandible truncation in one of the double
mutant embryos (Chrd
2/2,Tbx1
G.T/G.T, Table S1). This result
indicatesthatthecraniofacialphenotypecausedbylossofChrdisnot
suppressed by the Tbx1 mutation, suggesting that Tbx1 is not in turn
a modifier of Chrd.
Our data indicating that Chrd deficiency is a modifier of Tbx1
action raises the issue of the molecular basis of this modifier effect.
Previous work has suggested that Chrd activity promotes Tbx1
expression in the pharyngeal region of the mouse embryo. Tbx1
expression is reduced in this area of Chrd null embryos [12].
However, the pharyngeal tissues themselves are deficient from
early stages in the Chrd mutant (if the cryptic Tbx1 allele is also
present). Nonetheless, ectopic Chrd activity in early Xenopus
embryos can cause increased Tbx1 transcript levels [12]. In a
Figure 1. Phenotype of Chrd mutant embryos in 129S6 inbred and hybrid backgrounds. (A–G) Comparison of organ structures in wildtype
and Chrd mutant embryos at embryonic day (E) 15.5. Ears of Chrd
2/2 embryos are abnormally located and fail to form auricle structures (A, B).
Athymia, persistent truncus arteriosus (PTA; failure of outflow tract septation) and abnormal aortic arch artery structure are observed in the mutant
(C–E). Cleft palate (CP) is also a feature of the mutant embryos (F, G). (H) Penetrance of Chrd null mutation in various genetic backgrounds; it shows
complete penetrance in the 129S6 strain and partial penetrance in the F2 hybrid (129SB6F2) strain. (I) Phenotypic pattern of 129SB6F2-Chrd
2/2
embryos. The majority of embryos showed either a ‘Full phenotype’ (as defined in the main text) or no phenotype. Several embryos (11/97) showed
variable DGS-like phenotypes. Despite this variability, the embryos can be classified into two groups: those that retain DGS-like phenotypes (in red),
and those devoid of DGS-like phenotypes (in blue). a, aorta; cp, cleft palate; HPE, holoprosencephaly; p, pulmonary trunk; pta, persistent truncus
arteriosus; t, thymus.
doi:10.1371/journal.pgen.1000395.g001
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PLoS Genetics | www.plosgenetics.org 3 February 2009 | Volume 5 | Issue 2 | e1000395Figure 2. Characterization of a linked modifier of Chrd in the 129S6 strain. (A) Schematic diagram of mouse chromosome 16, showing three
genetic markers used and genotyping results of F2 hybrid DNAs using these markers. Information on the markers is shown in the table at the bottom
of the panel. The second marker rs4165069 shows the strongest co-segregation with the trait. The novel SSLP marker ‘ChTb03’ produces a 271 bp
long PCR fragment from 129S6, and 262 bp from B6 (Figure S4). (B) Cross between 129S6-Chrd
+/2 and B6-Tbx1
+/2 mice produced Chrd
+/2,Tbx1
+/2
embryos with highly penetrant 22q11DS phenotypes, supporting the existence of modifier linked to Chrd and suggesting the possibility of a
mutation in Tbx1 itself. (C) Sequencing of theTbx1 locus of 129S6-Chrd
+/+ and 129S6-Chrd
+/2 strains, revealing a specific point mutation (Tbx1
G.T)
located in the second intron of the 129S6-Chrd
+/2 allele (asterisk). (D) Genotyping results of F2 hybrid DNAs using theTbx1
G.T mutation as a SNP
marker, showing that it is more strongly linked to the phenotype than rs4165069. (E) Tbx1
G.T is located at an exon-intron boundary. Consensus, wild-
type, and mutant sequences encompassing the mutation are displayed. (F) RT-PCR analysis demonstrates that Tbx1
G.T disrupts normal splicing of
Tbx1 in 129S6 mice carrying the Chrd null allele. As a result of the point mutation, both exon skipping (left) and intron retention (right) occur in the
generation of Tbx1 mRNA, but very little normal message is produced. Diagrams of mRNA with asterisks (*) denote mutant splicing variants that
would invariably produce truncated Tbx1 protein.
doi:10.1371/journal.pgen.1000395.g002
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+/+,Tbx1
G.T/G.T and Chrd
2/2,Tbx1
+/+ mutant embryos. (A) Crossing scheme to generate recombinant animals.
129S6-Chrd
+/2 females were mated with 129S6 wild-type studs and offspring were screened for recombination of markers. (B) Penetrance of five
phenotypes associated with DGS from each different Tbx1 mutant class, displaying dosage-dependent rescue of craniofacial phenotypes. (C–H)
Chordin Is a Tbx1 Modifier
PLoS Genetics | www.plosgenetics.org 5 February 2009 | Volume 5 | Issue 2 | e1000395separate study on the role of BMP signaling in heart development,
we observe that BMP-soaked beads in the pharyngeal lumen
reduce the expression of Tbx1 (Choi et al., manuscript in
preparation). Such data support a model that Chrd expression in
the dorsal pharyngeal endoderm promotes Tbx1 expression in the
pharyngeal region, by antagonizing a repressive effect of BMP on
Tbx1 transcription.
To further test whether Chrd mutations alter Tbx1 expression in
vivo, we measured the amount of Tbx1 transcripts by in situ and
real-time quantitative PCR in the 129S6 strain (in the presence of
the Tbx1
G.T mutation) and in the B6 strain (without the Tbx1
mutation). In both cases, there was reduced expression (Figure 4) –
about 30% less in B6, despite pharyngeal tissues being fully formed
and the Tbx1 locus presumably wildtype. In sum, our data indicate
that Chrd has a modest but significant role in promoting Tbx1
expression. Such a decrease is insufficient to cause 22q11DS-like
defects on its own, but may compound the consequences of a Tbx1
hypomorphic allele.
Discussion
Our search for the modifier of Chrd identified an unexpected,
linked mutation in the Tbx1 locus in the 129S6-Chrd
+/2 strain,
which causes mis-splicing. Comparison of phenotypes between the
separated, isolated Tbx1
G.T/G.T and Chrd
2/2 mutations and
those associated with homozygosity for the original chromoso-
some, i.e. Chrd
2/2,Tbx1
G.T/G.T, allow us to make important
conclusions regarding the basis of the phenotypes we observed.
First, we now know that the 22q11DS-like defects seen in the
original 129S6-Chrd
2/2 mutant embryos were actually caused
primarily by the mutation in Tbx1. On its own, in both the 129S6
and B6 backgrounds, Chrd
2/2 causes a low penetrance of
moderate to severe mandibular truncations. Secondly, embryos
mutant for the hypomorphicTbx1
G.T/G.T mis-splicing allele show
several cardiac and pharyngeal defects nearly as severe as those of
the Tbx1 null mutants, but without the major craniofacial
phenotypes of the null (reduced pinna and cleft palate). Finally,
our results show that whereas homozygosity for the hypomorphic
Tbx1
G.T allele rarely results in major craniofacial defects alone, it
does so when Chrd is absent. In contrast, the cardiovascular defects
are unaffected. Thus, Chrd is a modifier specifically for the
craniofacial phenotypes of Tbx1 lesions.
The craniofacial defects associated with homozygosity for the
cryptic double mutant reflect a synergistic relationship between the
Chrd and Tbx1 lesions. Although there was a low penetrance of
striking mandibular outgrowth defects in Chrd
2/2 mutants, most
homozygotes (73%) looked normal. The Tbx1
G.T/G.T animals in
turn showed a limited penetrance of craniofacial defects that are
reminiscent of 22q11DS. Penetrance of low-set, reduced pinna
(outer ear) was approximately 20%, while cleft palate was about
50%. However, when the two mutations are together, all mutant
embryos develop fully penetrant, highly consistent craniofacial
phenotypes; these defects appear to be identical to those of Tbx1
2/2
null animals, with cleft palate, reduced, low-set ears, athymia,
Figure 4. Reduced expression of Tbx1 in 129S6- and B6-Chrd
2/2 embryos. In situ hybridization at 5-somite stage of Tbx1 in 129S6-Chrd
+/+
(A,C) and 129S6-Chrd
2/2 embryos (B,D), displaying reduced expression in pharyngeal area of homozygotes with a DGS-like phenotype. (E)
Quantitative PCR of Tbx1 mRNA in embryos of the genotypes B6-Chrd
+/+ and B6-Chrd
+/2 (n=8) versus B6-Chrd
2/2 (n=4), demonstrating a modest
but significant (p=0.029) reduction of Tbx1 expression despite the absence of a DGS-like phenotype in B6-Chrd
2/2 mutants.
doi:10.1371/journal.pgen.1000395.g004
Variable mandible defects in Chrd
2/2 mutant at late gestation stages. (C, D) Mild mandible outgrowth defect in B6-Chrd
2/2 mutant embryo
(arrowhead). (E–H) Total absence of mandibular elements accompanying incomplete midline structure (arrowhead) is displayed in lateral (E, F) and
ventral view (G, H) of 129S6-Chrd
2/2 mutant embryo. (I–L) Developmental defects of Chrd null, Tbx1 hypomorphic, and compound mutations. (I)
Organs that are defective in various classes of mutant embryos. (J) Chrd null mice display a truncated mandible phenotype at low penetrance. (K)
Tbx1 hypomorphic embryos develop very mild craniofacial defects (note partially dysmorphic ear) compared to Tbx1 null embryos.
doi:10.1371/journal.pgen.1000395.g003
Chordin Is a Tbx1 Modifier
PLoS Genetics | www.plosgenetics.org 6 February 2009 | Volume 5 | Issue 2 | e1000395persistant truncus arteriosis, etc (Figure 5). These phenotypes occur
against a background of the low-penetrance of severe mandibular
truncation defects caused by absence of Chrd per se, much more
pronounced than the subtle mandibular hypoplasia reported for the
Tbx1 null [3]. Therefore, the absence of Chrd leads to a synergistic
(as opposed to additive) worsening of the defects caused by the
hypomorphic Tbx1 allele, to generate the complete constellation of
craniofacial defects seen in the Tbx1
2/2 null and reminiscent of
22q11DS.
The Tbx1
G.T mutation we identified behaves according to the
genetic definition of a hypomorphic allele: Tbx1
G.T/G.T homo-
zygotes are less severely effected than homozygotes for a null allele,
while the compound heterozygote is intermediate in severity.
Molecular evidence to account for such reduced activity was
apparent in the transcripts produced by the mutant allele. The
mutation is predicted to disrupt normal splicing, and in fact we
observed via PCR analysis both exon skipping and intron
retention. In the latter case, reading frame-shifts result in nonsense
codons. The transcript resulting from exon skipping would encode
a truncated product lacking 25% of the T-box domain, essential
for the proper function of the protein – if any protein is stably
produced. In addition, these abnormal transcripts account for
most of the spliceforms produced by the allele; we amplified little
transcript corresponding to the correctly spliced wildtype version
from Tbx1
G.T/G.T homozygotes.
The consequences of the cryptic Tbx1
G.T/G.T allele linked to
Chrd in the initial 129S6 background account for much of the
phenotype of Chrd
2/2 mutants as previously reported [12].
Nevertheless, our genomic scan to assess the possibility of
modifiers suggested more than one modifier was present. Thus
there may be additional modifier(s) in the 129S6 background that
influence the Chrd
2/2,Tbx1
G.T/G.T phenotype. Such lesions
could be outside the Chrd,Tbx1 region, or even within it – the
coding regions of these genes are approximately 2 million bases
apart (Mouse Genome Informatics). To prove that only the Chrd
targeted mutation and the cryptic Tbx1 splice site mutation (but no
other 129S6 allele) are sufficient for the full phenotype would
require reconstituting only these mutations in a different inbred
strain, a daunting task. We note that the behaviors of Chrd and
Tbx1 alleles independently do not appear to be 129S6-specific. For
Chrd
2/2 embryos, the penetrance and expressivity of the mandible
phenotype in the 129S6 and B6 strains are quite comparable
(Table S1). In the case of Tbx1, alleles have been made and studied
in multiple strains and produced very consistent phenotypes (our
observations, [2,3]). Altogether, it seems likely that if there are
additional specific modifiers at play, they have a very minor role.
Previous work and our unpublished observations suggest that
Chrd functions to promote Tbx1 expression in the pharyngeal
region. When we assayed Tbx1 expression in Chrd mutants with or
without the cryptic Tbx1 hypomorphic mutation, consistent results
were observed. In both 129S6- and B6-Chrd
2/2 embryos, there
was mild but significant reduction of Tbx1 expression when
compared to the wildtype embryos (Figure 4). Nevertheless, in all
three backgrounds tested, Chrd null animals free of Tbx1
G.T are
viable and show no pharyngeal defects. Thus the decrease of Tbx1
expression in pure Chrd mutants is insufficient to cause a
phenotype; however, loss of this activity could be a contributing
factor in the functional synergy between the Chrd null and
Tbx1
G.T mutations in causing a more severe DGS-like phenotype
than the hypomorphic Tbx1
G.T mutation alone.
We note that Chrd
2/2,Tbx1
+/G.T mice very rarely show Tbx1
mutant phenotypes (1/53 in the F2 hybrids). Thus it is possible
that the reduction in functional Tbx1 protein caused by a single
allele of Tbx1
+/G.T, compounded by the moderately decreased
Tbx1 expression caused by loss of Chrd, is in rare instances
sufficient to generate phenotypes similar to 22q11DS.
Tbx1 also shows genetic interactions with other mutations both
within and outside the DCR [10,11]. However, no second-site
mutation has been found previously that can account for why
DCR or Tbx1 mutations are sometimes associated with a
particular defect but sometimes not. The result reported here
show that Chrd is a modifier for the craniofacial anomalies ofTbx1
mutations, demonstrating the existence of a second-site modifier
for a specific subset of the phenotypes associated with 22q11DS.
Materials and Methods
Mouse Strains and Genotyping
The Chrd null allele (Chrd
tm1Emdr) was generated previously using
R1 ES cells [12]. To generate outbred Chrd stock [18], germline
chimeras were mated to random outbred ICR females, with
backcrossing of F1 founders to ICR. To generate 129S6 inbred
stock, germline chimeras were mated to 129S6/SvEvTac
(Taconic) wild type mice, and Chrd heterozygotes backcrossed for
Figure 5. Developmental defects of Chrd, Tbx1, and compound mutants. Organs that are defective in the various classes of Chrd and/or Tbx1
mutant embryos studied here. Degree of penetrance of phenotypes reminiscent of 22q11DS is shown by variable intensity of red shading, as defined
to the upper right of the figure. (A) Normal morphology (indicated by green shading) of organs sensitive to loss of Chrd and/or Tbx1 and their
location in wildtype embryos: mx, maxilla; mn, mandible; e, ear; t, thymus; h, heart; CP, cleft palate; ME, malformed ear; AT, athymia; PTA, persistent
truncus arteriosus. (B) Chrd null mice display a markedly truncated mandible phenotype at low penetrance (blue shading), while other structures are
unaffected. (C) Tbx1
G.T/G.T embryos sometimes develop mild craniofacial defects (note partially dysmorphic ear) compared to Tbx1
2/2 null embryos,
while AT and PTA are fully penetrant. We did not quantitatively score for the presence of previously reported possible subtle mandibular
dysmorphology associated with loss of Tbx1 (yellow, NA: not addressed, [3]), quite distinct from the Chrd truncation phenotype. (D) In the Chrd
2/2;
Tbx1
G.T/G.T double mutant embryos, all indicated organs develop abnormally with complete penetrance, with an overall phenotype identical with
(E) Tbx1
2/2 null embryos. Rarely, these defects are superimposed on mandibular truncations (blue), as seen at similarly low penetrance in Chrd
2/2
mutants.
doi:10.1371/journal.pgen.1000395.g005
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+/2
male was crossed to C57BL/6J wild-type (Jackson Laboratory)
females. Resulting heterozygous males were subsequently back-
crossed with C57BL/6J wild-type females for 10 generations. Chrd
and Tbx1
tm1Bld were genotyped via PCR as previously described
[12]. To type the Tbx1
G.T mutation, regions encompassing the
mutation were PCR-amplified (forward: 59- AGCAGGGCAG-
GAACAGTCT-39, reverse: 59- CTGCCTGGCCAGA-
GAAGTTA-39), cut with DpnII (New England Biolab), and
resolved by agarose gel electrophoresis. For partial genome
scanning to find rough general locations of major Chrd modifiers,
we searched for microsatellite marker differences between 129S6
and C57BL6 strains (http://www.informatics.jax.org/searches/
polymorphism_form.shtml; www.cidr.jhmi.edu/mouse/mmset.
html). We used 154 markers, with an average interval of
approximately 22.2Mb. We designed appropriate PCR primers
and amplified corresponding regions from F2 hybrid animals.
Isolation of RNA and Reverse Transcriptase-PCR (RT-PCR)
To assess Tbx1 splicing, total RNA was prepared from E9.5
embryos and subjected to RT-PCR. Pharyngeal tissues were
homogenized and treated with TRIZOL Reagent (Invitrogen).
Remaining tissues were used for genotyping. After further
purification, the RNA pellet was dried and resuspended in
DEPC-water for subsequent reverse transcription (RT) with
random hexamer and mouse mammary tumour virus (MMTV)
RT (Invitrogen). Resulting cDNA was used as a template for PCR.
The following primers were used for testing Tbx1 splicing:
TbxRT1F 59-TTTGTGCCCGTAGATGACAA-39 (forward);
TbxRT2R 59-TCATCCAGCAGGTTATTGGTC-39 (reverse);
TbxRT3R 59-AATCGGGGCTGATATCTGTG-39 (reverse);
TbxRT4F 59-TGTGGGACGAGTTCAATCAG-39 (forward).
Skeletal Preparation
Skeletal tissues were prepared and visualized as previously
described [18].
Supporting Information
Figure S1 Absence of Tbx1 results in phenotypes identical to
Chrd null homozygotes in a 129S6 inbred genetic background.
Phenotype of Tbx1
2/2 embryo at E16.5 includes abnormal inner
and outer ears (A, B), absence of thymus, PTA (C–E) and cleft
palate (F,G). a, aorta; cp, cleft palate; p, pulmonary trunk; pta,
persistent truncus arteriosus; t, thymus.
Found at: doi:10.1371/journal.pgen.1000395.s001 (0.3 MB TIF)
Figure S2 Outer ear morphologies in embryos of different Chrd
genotypes. (A, B) Normal ears of Chrd
+/+ and Chrd
+/2 embryos at
E18.5, respectively. (C–F) Ears of F2 Chrd hybrid mutants
(129SB6F2-Chrd
2/2) displaying partially-defective outer ear mor-
phologies. (G) Representative ear of inbred Chrd mutant embryo,
showing the total failure of auricle formation.
Found at: doi:10.1371/journal.pgen.1000395.s002 (0.9 MB TIF)
Figure S3 Status of Tbx1 locus in various relevant strains. A
number of substrains of 129, the C57BL/6 strain and the parental
R1 ES cell line used for targeting are devoid of Tbx1
G.T
(represented by +/+genotype). The diagram shows the lineage
relationship of many of these strains.
Found at: doi:10.1371/journal.pgen.1000395.s003 (0.2 MB TIF)
Figure S4 Sequences of novel SSLP locus ChTb03 from B6 and
129S6 strains. Number of ‘CTT’ repetitions differs between the
two strains, causing different lengths of amplified PCR product.
Bold sequences are primers for PCR amplification.
Found at: doi:10.1371/journal.pgen.1000395.s004 (0.02 MB
DOC)
Table S1 Penetrance of mandible defect phenotype in Chrd
mutant embryos.
Found at: doi:10.1371/journal.pgen.1000395.s005 (0.02 MB
DOC)
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